Major Investor Group Exits Monopar Therapeutics, Liquidating Stake
Summary
Tactic Pharma LLC and associated individuals have liquidated their beneficial ownership in Monopar Therapeutics, ceasing to be a 5% reporting group.
Key Events
-
Investor Group Exits
Tactic Pharma LLC, along with Chandler Robinson and Michael Brown, completed a liquidating distribution of their shares on January 28, 2026.
-
Cease 5% Ownership
As a result of the distribution, the reporting persons individually and collectively ceased to be beneficial owners of more than five percent of Monopar Therapeutics' common stock.
-
Final 13D Amendment
This filing represents the final amendment to their Schedule 13D, indicating a complete withdrawal from their reporting obligations for the company.
Analysis
This Schedule 13D/A marks the final amendment for Tactic Pharma LLC, Chandler Robinson, and Michael Brown, as they have completed a liquidating distribution of their holdings in Monopar Therapeutics. As a result, the reporting persons no longer collectively hold a beneficial ownership stake exceeding 5%, signaling a complete exit from their Schedule 13D reporting obligations. This significant reduction in institutional ownership could be perceived negatively by the market, indicating a loss of conviction from a previously substantial investor group.
At the time of this filing, MNPR was trading at $61.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $412.1M. The 52-week trading range was $26.06 to $105.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.